PURPOSE The Korea Central Cancer Registry (KCCR) program completed a nationwide hospital-based cancer registry to provide basic statistical data on cancer incidence. MATERIALS AND METHODS In 2000, 131 hospitals participated in the KCCR program. All cancer registry data, which were submitted by the participating hospitals during the year, were reviewed and analyzed by the committee members. RESULTS Of the 94,474 cases that were registered, 7,735 (8.2%) duplication cases were excluded. Of the remaining 86,739 cases, 2,893 cases (3.3%) of carcinoma in situ (morphology code/2) were excluded, leaving a final total of 83,846 cases for analysis, 48,005 (57.3%) male and 35,841 (42.7%) female. The leading age group was 60-64years (15.1%). The six leading primary cancer sites in the order of their relative frequency were the stomach (20.8%), lung (12.2%), liver (12.2%), colorectum (10.3%), breast (6.5%), and uterine cervix (4.5%). In males, the three leading primary cancer sites were the stomach (24.5%), liver (16.3%), and lung (16.3%). In females, the stomach (15.8%), breast (15.1%), and uterine cervix (10.6%). Among the 1,126 cases of childhood malignancies, leukemia (32.7%) was the most common cancer type. CONCLUSION We report our analysis of the KCCR data from 131 nationwide hospitals during 2000.
Citations
Citations to this article as recorded by
Morin Hydrate Sensitizes Hepatoma Cells and Xenograft Tumor towards Cisplatin by Downregulating PARP-1-HMGB1 Mediated Autophagy Mahendra Pal Singh, Tejinder Pal Khaket, Vivek K. Bajpai, Saleh Alfarraj, Se-Gie Kim, Lei Chen, Yun Suk Huh, Young-Kyu Han, Sun Chul Kang International Journal of Molecular Sciences.2020; 21(21): 8253. CrossRef
Helicobacter pyloriInfection and Intestinal Metaplasia among Healthy Adolescents Ji Sook Park, Kyuyol Rhie, Ji-Hyun Seo, Eo Young Ryu, Hyun-Jin Kim, Hong-Jun Kim, Jae-Young Lim, Hyang-Ok Woo, Seung-Chul Baik, Woo-Kon Lee, Myung-Je Cho, Kwang-Ho Rhee, Gyung-Hyuck Ko, Hee-Shang Youn The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2015; 15(4): 243. CrossRef
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer In Gyu Hwang, Joung-Soon Jang, Sung Yong Oh, Myung Hwan Rho, Suee Lee, Young Suk Park, Joon Oh Park, Eun Mi Nam, Hyo Rak Lee, Hyun Jung Jun, Kyong-Choun Chi Cancer Chemotherapy and Pharmacology.2015; 75(4): 757. CrossRef
Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer Seung Tae Kim, Hye-Lim Jang, Jeeyun Lee, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Min Gew Choi, Jae Moon Bae, Tae Sung Sohn, Jae Hyung Noh, Sung Kim, Kyoung-Mee Kim, Won Ki Kang, Joon Oh Park Translational Oncology.2015; 8(4): 288. CrossRef
Outcomes of advanced gastric cancer in young adult patients treated with first-line combination chemotherapy Hyun-Jun Kim, Kyoung Kim International Journal of Cancer Therapy and Oncology.2015; 3(4): 344. CrossRef
Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows PotentIn VitroAntitumor Activity in Gastric Cancer Cell Lines withFGFR2Amplification Seung Tae Kim, Hye-Lim Jang, Su Jin Lee, Jeeyun Lee, Yoon-La Choi, Kyoung-Mee Kim, Jeonghee Cho, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Masakazu Yashiro, Won Ki Kang, Joon Oh Park Molecular Cancer Therapeutics.2014; 13(11): 2527. CrossRef
A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers Jeeyun Lee, Sung Kim, Phillip Kim, Xinjun Liu, Tani Lee, Kyoung-Mee Kim, In-Gu Do, Joon Oh Park, Se Hoon Park, Jiryeon Jang, Nicholas Hoe, Gulia Harvie, Anne Kuller, Anjali Jain, Gary Meyer, Glen Leesman, Young Suk Park, Min Gew Choi, Tae Sung Sohn, Jae M PLoS ONE.2013; 8(1): e54644. CrossRef
Plasma human mammaglobin mRNA associated with poor outcome in patients with breast cancer G.-W. Lee, J.-Y. Kim, E.-H. Koh, D. Kang, D.S. Choi, K.-Y. Maeng, J.-S. Lee Genetics and Molecular Research.2012; 11(4): 4034. CrossRef
P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients Hee Kyung Ahn, Jiryeon Jang, Jeeyun Lee, Hoon Park Se, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung-Mee Kim, Won Ki Kang Translational Oncology.2011; 4(6): 345. CrossRef
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer Taekyu Lim, Jeeyun Lee, Duk Joo Lee, Ha Yeon Lee, Boram Han, Kyung Kee Baek, Hee Kyung Ahn, Su Jin Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung-Mee Kim, Won Ki Kang Cancer Chemotherapy and Pharmacology.2011; 68(1): 255. CrossRef
Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models Kyung Kee Baek, Jung-Hoon Kim, Ji Eun Uhm, Se Hoon Park, Jeeyun Lee, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim Oncology.2011; 80(3-4): 167. CrossRef
A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer JUNG HAN KIM, HYEONG SU KIM, DAE RO CHOI, GEUNDOO JANG, JUNG HYE KWON, HO YOUNG KIM, JOO YOUNG JUNG, HYO JUNG KIM, HUN HO SONG, YUN HO SHIN, SO YOUNG JUNG, BYUNG CHUN KIM, DAE YOUNG ZANG Oncology Letters.2011; 2(6): 1253. CrossRef
Effect of Benzothiazole based conjugates in causing apoptosis by Regulating p53, PTEN and MAP Kinase proteins affecting miR-195a and miR-101-1 SNCVL Pushpavalli, M Janaki Ramaiah, Ch Srinivas, Debasmita Mukhopadhya, JL Aditya, Ravindra M Kumbhare, Utpal Bhadra, Manika Pal Bhadra Cancer Cell International.2011;[Epub] CrossRef
Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer Su-Hee Cho, Se-Il Go, Gyeong-Won Lee, Jung Hun Kang, Hoon-Gu Kim, Seok Hyun Kim, Yu Ji Cho, Yi Yeong Jeong, Ho-Cheol Kim, Jong Duk Lee, Young Sil Hwang Lung Cancer.2010; 69(1): 94. CrossRef
Lung cancer risk and cigarette smoking, lung tuberculosis according to histologic type and gender in a population based case–control study Sue K. Park, Lisa Y. Cho, Jae Jeong Yang, Boyoung Park, Soung Hoon Chang, Kun-Sei Lee, Hyeongsu Kim, Keun-Young Yoo, Choon-Taek Lee Lung Cancer.2010; 68(1): 20. CrossRef
Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer Jung Hye Kwon, Jung Han Kim, Jung-Ae Lee, Hyun Chun Shin, Hyo Jung Kim, Hun Ho Song, Joo Young Jung, Ho Young Kim, Dae Ro Choi, Hyeong Su Kim, Young-iee Park, Dae Young Zang Cancer Chemotherapy and Pharmacology.2010; 66(5): 889. CrossRef
Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer Hyo Jin Lee, Do Yeun Cho, Ji Chan Park, Sang Byung Bae, Kyu Taek Lee, In Sung Cho, Chang Soon Han, Suk Young Park, Hwan Jung Yun, Samyong Kim Cancer Chemotherapy and Pharmacology.2009; 63(3): 427. CrossRef
Phase II study of S-1 and irinotecan combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05-02 Hye J KANG, Sang H CHO, Suk J OH, Sung H YANG, Moon H LEE, Eun-Kee SONG, Hyun C CHUNG, Im I NA, Baek-Yeol RYOO Asia-Pacific Journal of Clinical Oncology.2009; 5(1): 46. CrossRef
A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma Ji Eun Uhm, Joon Oh Park, Jeeyun Lee, Young Suk Park, Se Hoon Park, Byung Chul Yoo, Seung Woon Paik, Kwang Cheol Koh, Won Ki Kang, Ho Yeong Lim Cancer Chemotherapy and Pharmacology.2009; 63(5): 929. CrossRef
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer Seong Yoon Yi, Young Suk Park, Hyo Song Kim, Hyun Jung Jun, Kyoung Ha Kim, Myung Hee Chang, Min Jae Park, Ji Eun Uhm, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Jong Kyun Lee, Kyu Taek Lee, Ho Yeong Lim, Won Ki Kang Cancer Chemotherapy and Pharmacology.2009; 63(6): 1141. CrossRef
A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer Kyoung Ha Kim, Young Suk Park, Myung Hee Chang, Hyo Song Kim, Hyun Jung Jun, Jieun Uhm, Seong Yoon Yi, Do Hyoung Lim, Sang Hoon Ji, Min Jae Park, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang Cancer Chemotherapy and Pharmacology.2009; 64(2): 347. CrossRef
A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer Sang Hoon Ji, Do Hyoung Lim, Seong Yoon Yi, Hyo Song Kim, Hyun Jung Jun, Kyoung Ha Kim, Myung Hee Chang, Min Jae Park, Ji Eun Uhm, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang BMC Cancer.2009;[Epub] CrossRef
Impact of Standardized Rhus verniciflua Stokes Extract as Complementary Therapy on Metastatic Colorectal Cancer: A Korean Single-Center Experience Sang-hun Lee, Won-cheol Choi, Seong-woo Yoon Integrative Cancer Therapies.2009; 8(2): 148. CrossRef
Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma Dongho Choi, Hyo Won Lee, Kyung Yul Hur, Jae Joon Kim, Gyeong-Sin Park, Si-Hyong Jang, Young Soo Song, Ki-Seok Jang, Seung Sam Paik World Journal of Gastroenterology.2009; 15(18): 2258. CrossRef
Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy Se Hoon Park, Moon Sook Cho, Young Saing Kim, Junshik Hong, Eunmi Nam, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon Kee Lee Quality of Life Research.2008; 17(2): 207. CrossRef
Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study Se Hoon Park, Young Saing Kim, Junshik Hong, Jinny Park, Eunmi Nam, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon Kee Lee, Min Chung Anti-Cancer Drugs.2008; 19(3): 303. CrossRef
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer H J Kang, H M Chang, T W Kim, M-H Ryu, H-J Sohn, J H Yook, S T Oh, B S Kim, J-S Lee, Y-K Kang British Journal of Cancer.2008; 98(2): 316. CrossRef
Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study Yeul Hong Kim, Hyun Cheol Chung, Won Ki Kang, Sook Ryun Park, Chul Soo Kim, Tae-Yue Kim, Sang Won Shin, Byung-Joo Park, Soo Jin Cha, Yung-Jue Bang Cancer Chemotherapy and Pharmacology.2008; 62(2): 263. CrossRef
Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer Se Hoon Park, Junshik Hong, Young Saing Kim, Yujin Kim, Sun Young Kyung, Chang Hyeok An, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jeong, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee Lung Cancer.2008; 62(1): 72. CrossRef
Comparison of the 13C-urea breath test and the endoscopic phenol red mucosal pH test in the quantification of Helicobacter pylori infection loading Young-Seok Cho, Hiun-Suk Chae, Se Na Jang, Jin-Soo Kim, Hye Suk Son, Hyung-Keun Kim, Byung-Wook Kim, Sok-Won Han, Kyu-Yong Choi, Hae Kyung Lee, Eun Deok Chang The Korean Journal of Internal Medicine.2008; 23(3): 134. CrossRef
Salvage Chemotherapy With Biweekly Irinotecan, Plus 5-Fluorouracil and Leucovorin in Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine, Platinum, and Taxane Sun Jin Sym, Min-Hee Ryu, Jae-Lyun Lee, Heung Moon Chang, Tae Won Kim, Sung Sook Lee, Jung Shin Lee, Yoon-Koo Kang American Journal of Clinical Oncology.2008; 31(2): 151. CrossRef
Adenosine Kinase Gene Expression in Human Colorectal Cancer S. Giglioni, R. Leoncini, E. Aceto, A. Chessa, S. Civitelli, A. Bernini, G. Tanzini, F. Carraro, A. Pucci, D. Vannoni Nucleosides, Nucleotides and Nucleic Acids.2008; 27(6-7): 750. CrossRef
Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation Therapy Jeeyun Lee, Cheol Keun Park, Joon Oh Park, Taekyu Lim, Young Suk Park, Ho Yeong Lim, Inkyoung Lee, Tae Sung Sohn, Jae Hyung Noh, Jin Seok Heo, Sung Kim, Do Hoon Lim, Kyoung-Mee Kim, Won Ki Kang Clinical Cancer Research.2008; 14(1): 82. CrossRef
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma Jeeyun Lee, Kee‐Taek Jang, Chang‐Seok Ki, Taekyu Lim, Young Suk Park, Ho Yeong Lim, Dong‐Wook Choi, Won Ki Kang, Keunchil Park, Joon Oh Park Cancer.2007; 109(8): 1561. CrossRef
Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis Won-Suk Lee, Min Jung Kim, Seong Hyeon Yun, Ho-Kyung Chun, Woo Yong Lee, Sung-Joo Kim, Seong-Ho Choi, Jin-Seok Heo, Jae Won Joh, Yong Il Kim Langenbeck's Archives of Surgery.2007; 393(1): 13. CrossRef
Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first‐line therapy in advanced nonsmall cell lung cancer Se Hoon Park, Soo Jin Choi, Sun Young Kyung, Chang Hyeok An, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jeong, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee Cancer.2007; 109(4): 732. CrossRef
A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim Cancer Research and Treatment.2007; 39(1): 6. CrossRef
Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer Jae Yun Lim, Jae Yong Cho, Yong Han Paik, Dong Ki Lee, Sang In Lee, Hyo Jin Park, Se Joon Lee, Kwan Sik Lee, Dong Sup Yoon, Seung Ho Choi Oncology.2007; 73(1-2): 2. CrossRef
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma J. Lee, W.K. Kang, J.M. Kwon, S.Y. Oh, H.R. Lee, H.J. Kim, B.B. Park, H.Y. Lim, M.J. Han, J.O. Park, Y.S. Park Annals of Oncology.2007; 18(1): 88. CrossRef
Malignancies in Korean Patients with Inflammatory Myopathy Sang-Won Lee, Sang Youn Jung, Min-Chan Park, Yong-Beom Park, Soo-Kon Lee Yonsei Medical Journal.2006; 47(4): 519. CrossRef
Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma Se Hoon Park, Yeon Ho Park, Jeong Nam Lee, Soo‐Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee Cancer.2006; 106(2): 361. CrossRef
The Synergism between Belotecan and Cisplatin in G astric Cancer Joo Young Jung, Sang Hyun Song, Tae-Young Kim, Jung Hyun Park, Hyun-Soon Jong, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang, Noe Kyoung Kim Cancer Research and Treatment.2006; 38(3): 159. CrossRef
Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil Se Hoon Park, Woon Kee Lee, Min Chung, Yuna Lee, Sang Hoon Han, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee Anti-Cancer Drugs.2006; 17(2): 225. CrossRef
Thalidomide for Treating Metastatic Hepatocellular Carcinoma: A Pilot Study Sang Hoon Han, Se Hoon Park, Jung Ho Kim, Jong Jun Lee, So Young Kwon, Oh Sang Kwon, Sun Suk Kim, Ju Hyun Kim, Keon Kug Kim, Yeon Ho Park, Jeong Nam Lee, Eunmi Nam, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee The Korean Journal of Internal Medicine.2006; 21(4): 225. CrossRef
Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer Se Hoon Park, Jeeyun Lee, Se Hoon Lee, Joon Oh Park, Kihyun Kim, Won Seog Kim, Chul Won Jung, Young Suk Park, Won Ki Kang, Keunchil Park, Seonwoo Kim, Soo Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee Cancer Chemotherapy and Pharmacology.2006; 57(1): 91. CrossRef
A Pilot Study of Cisplatin, Irinotecan, Leucovorin and 5-fluorouracil (PILF) Combination Chemotherapy for Advanced Gastric Cancer Se Hoon Park, Soo Yeon Jeon, Kwang Il Ko, Eunmi Nam, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon Ki Lee, Min Chung Cancer Research and Treatment.2006; 38(3): 121. CrossRef
Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy Se Hoon Park, Woon Ki Lee, Min Chung, Soo-Mee Bang, Eun Kyung Cho, Jae Hoon Lee, Dong Bok Shin Cancer Chemotherapy and Pharmacology.2006; 57(3): 289. CrossRef
Progression of Atrophic Gastritis and Intestinal Metaplasia Drives Helicobacter pylori Out of the Gastric Mucosa Hae Yeon Kang, Nayoung Kim, Young Soo Park, Jin-Hyeok Hwang, Jin-Wook Kim, Sook Hyang Jeong, Dong Ho Lee, Hyun Chae Jung, In Sung Song Digestive Diseases and Sciences.2006; 51(12): 2310. CrossRef
Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma Se Hoon Park, Yuna Lee, Sang Hoon Han, So Young Kwon, Oh Sang Kwon, Sun Suk Kim, Ju Hyun Kim, Yeon Ho Park, Jeong Nam Lee, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee BMC Cancer.2006;[Epub] CrossRef
Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer Keon Woo Park, Jin Seok Ahn, Young Suk Park, Jeeyun Lee, Jung Hoon Kang, Joon Oh Park, Ho Yeong Lim, Young-Hyuck Im, Won Ki Kang, Keunchil Park, Soon Il Lee Cancer Chemotherapy and Pharmacology.2006; 59(1): 17. CrossRef
Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil and Low Dose Leucovorin in Patients with Advanced Colorectal Cancer Yoon Mi Shin, Hae Suk Han, Seong Woo Lim, Byung Chul Kim, Kyung Suck Cheoi, Young Ook Eum, Seung Taek Kim, Ki Hyeong Lee Cancer Research and Treatment.2005; 37(5): 284. CrossRef
Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy H J Kang, H M Chang, T W Kim, M-H Ryu, H J Sohn, J H Yook, S T Oh, B S Kim, J-S Lee, Y-K Kang British Journal of Cancer.2005; 92(2): 246. CrossRef
A Phase II Study of Epirubicin, Cisplatin and Capecitabine Combination Chemotherapy in Patients with Metastatic or Advanced Gastric Cancer Eun Kyung Cho, Woon Ki Lee, Seok-Ah Im, Soon Nam Lee, Se Hoon Park, Soo-Mee Bang, Dong Kyun Park, Yeon Ho Park, Dong Bok Shin, Jae Hoon Lee Oncology.2005; 68(4-6): 333. CrossRef
Interleukin‐1B (IL‐1B) polymorphisms and gastric mucosal levels of IL‐1β cytokine in Korean patients with gastric cancer Young‐Woon Chang, Jae‐Young Jang, Nam‐Hoon Kim, Jae Won Lee, Hyo Jung Lee, Woon Won Jung, Seok‐Ho Dong, Hyo‐Jong Kim, Byung‐Ho Kim, Joung‐Il Lee, Rin Chang International Journal of Cancer.2005; 114(3): 465. CrossRef
Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer S C Oh, K H Park, I K Choi, S Y Yoon, S J Kim, J H Seo, C W Choi, B S Kim, S W Shin, J S Kim, Y H Kim British Journal of Cancer.2005; 92(5): 827. CrossRef
Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer Se Hoon Park, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon KI Lee, Min Chung BMC Cancer.2005;[Epub] CrossRef
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach Sung Kim, Do Hoon Lim, Jeeyun Lee, Won Ki Kang, John S. MacDonald, Chan Hyung Park, Se Hoon Park, Se-Hoon Lee, Kihyun Kim, Joon Oh Park, Won Seog Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Tae Sung Sohn, Jae Hyung Noh, Jin Seok Heo, Yong Il Kim, International Journal of Radiation Oncology*Biology*Physics.2005; 63(5): 1279. CrossRef
Oxaliplatin, Folinic Acid and 5-Fluorouracil (FOLFOX-4) Combination Chemotherapy as Second-line Treatment in Advanced Colorectal Cancer Patients with Irinotecan Failure: A Korean Single-center Experience Se Hoon Park, Ju Young Sung, Sang-Hoon Han, Jeong Heum Baek, Jae Hwan Oh, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee Japanese Journal of Clinical Oncology.2005; 35(9): 531. CrossRef
CASPASE-8 Gene Is Inactivated by Somatic Mutations in Gastric Carcinomas Young Hwa Soung, Jong Woo Lee, Su Young Kim, Jin Jang, Yong Gyu Park, Won Sang Park, Suk Woo Nam, Jung Young Lee, Nam Jin Yoo, Sug Hyung Lee Cancer Research.2005; 65(3): 815. CrossRef
Impact of the New AJCC Staging System and Adjuvant Treatment in Rectal Cancer Shin Ae Lee, Hyuk-Chan Kwon, Min Ah Park, Chang Kil Jung, Sung-Hyun Kim, Ki-Jae Park, Hong-Jo Choi, Hyung-Sik Lee, Mee Sook Roh, Jae-Seok Kim, Hyo-Jin Kim Cancer Research and Treatment.2004; 36(2): 121. CrossRef
Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer: a Pilot Study Myung-Ju Ahn, Ho-Suck Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Oh Young Lee, Ho-Soon Choi, Sung-Joon Kwon Cancer Research and Treatment.2004; 36(3): 182. CrossRef
Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer S-H Lee, W K Kang, J Park, H Y Kim, J H Kim, S I Lee, J O Park, K Kim, C W Jung, Y S Park, Y-H Im, M H Lee, K Park British Journal of Cancer.2004; 91(1): 18. CrossRef
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma Jeeyun Lee, Joon Oh Park, Won Seog Kim, Se Hoon Park, Keon Woo Park, Moon Seok Choi, Joon Hyoek Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Jaewon Joh, Kihyun Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H. Lee, Keunchi Cancer Chemotherapy and Pharmacology.2004; 54(5): 385. CrossRef
Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer Jinny Park, Byung Bae Park, Jee Youn Kim, Se-Hoon Lee, Soon Il Lee, Ho Young Kim, Jung Han Kim, Se Hoon Park, Kyung-Eun Lee, Joon Oh Park, Kihyun Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H. Lee, Keunchil Park Clinical Cancer Research.2004; 10(13): 4383. CrossRef
A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers Jinny Park, Yong Chan Ahn, Hojoong Kim, Se-Hoon Lee, Se Hoon Park, Kyung-Eun Lee, Do Hoon Lim, JoonOh Park, Kihyun Kim, Chul Won Jung, Young-Hyuck Im, Won Ki Kang, Mark H. Lee, Keunchil Park Lung Cancer.2003; 42(2): 227. CrossRef
Delta 13C‐urea breath test value is a useful indicator for Helicobacter pylori eradication in patients with functional dyspepsia YOUNG‐WOON CHANG, SUN‐KEE MIN, KYUNG‐JIN KIM, YO‐SEOB HAN, JOO‐HEE LEE, SEOK‐HO DONG, HYO‐JONG KIM, BYUNG‐HO KIM, JOUNG‐IL LEE, RIN CHANG Journal of Gastroenterology and Hepatology.2003; 18(6): 726. CrossRef
Postoperative chemoradiotherapy for gastric cancer S.H. Park, D.Y. Kim, J.S. Heo, D.H. Lim, C.K. Park, K.W. Lee, S.H. Choi, T.S. Sohn, S. Kim, J.H. Noh, Y.I. Kim, J.O. Park, K. Kim, W.S. Kim, C.W. Jung, Y.H. Im, M.H. Lee, K. Park, C.H. Park, W.K. Kang Annals of Oncology.2003; 14(9): 1373. CrossRef
Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients Young‐Woon Chang, Yo‐Seob Han, Dong‐Keun Lee, Hyo‐Jong Kim, Hyun‐Seok Lim, Jeong‐Seop Moon, Seok‐Ho Dong, Byung‐Ho Kim, Joung‐Il Lee, Rin Chang International Journal of Cancer.2002; 101(5): 469. CrossRef
PURPOSE To evaluate the results of adriamycin-based adjuvant chemotherapy with or without high dose chemotherapy (HDC) with stem cell transplantation (SCT) in breast cancer with 10 or more positive axillary nodes. MATERIALS AND METHODS Seventy-one breast cancer patients who had undergone surgery and had 10 or more positive axillary nodes were included in this study held between January 1997 and December 1999. The pathologic and clinical records were reviewed retrospectively. RESULTS Twenty-nine patients were treated with adriamycin followed by 8 courses of CMF (group I); 22 patients received 4 courses of adriamycin and 7 patients received 3 courses of adriamycin. Twenty-six patients received median 6 courses of CAF (group II) and 16 patients underwent HDC and autologous SCT (group III). With a median follow-up of 27.1 months, relapses were observed in 24 patients (33.8%) and the 3-year disease-free survival (DFS) rate was 57.1%; group I/II 55.4%, and group III 62.7%. The three-year overall survival (OS) rate was 86.1%; group I/II 83.0%, group III 93.8%.
There were no difference in the 3-year DFSs or in the OSs of group I and group II. However, patients who received only 3 courses of the sequential adriamycin in group I showed a significantly poorer 3-year OS than those that received 4 courses of adriamycin (42.9% vs. 95.5%). CONCLUSION Our study shows that adriamycin-containing combination chemotherapy is as effective as HDC with SCT in patients with 10 or more positive axillary lymph nodes judging by 3-year DFS and OS, and shows that three courses of adriamycin seems to be inadequate.
Citations
Citations to this article as recorded by
Alternative Therapy and Abnormal Liver Function During Adjuvant Chemotherapy in Breast Cancer Patients Jin-Hee Ahn, Sung-Bae Kim, Mi Ra Yun, Jung-Shin Lee, Yoon-Koo Kang, Woo Kun Kim Journal of Korean Medical Science.2004; 19(3): 397. CrossRef
PURPOSE Axillary lymph node metastases are the single most important predictor of overall survival in patients with breast cancer. Micrometastases are defined by the American Joint Committee on Cancer as tumor foci less than or equal to 2 mm in greatest dimension. Recently, up to 30% of breast cancer patients were reported to have micrometastases. In this paper, to assess the rate of micrometastases in patients with stage I breast cancer, we attempted to determine the most useful marker of the micrometastases in node negative cases by routine histopathologic examination of regional lymph nodes and comparison of the results with the influencing factors on prognosis. MATERIALS AND METHODS We performed immunohisto chemical staining for pancytokeratin, cytokeratin 7, cytokeratin 20 and CEA to identify which protein was the most useful marker for the detection of micrometastases in 86 node negative cases and determined the correlation between histological and clinical data. RESULTS A total of 5 lymph nodes in 5 separate cases showed micrometastases among the total 1,296 lymph nodes and 86 cases. The rates of micrometastases of lymph nodes and cases were 0.38% and 5.8%, respectively. The tumor type of micrometastasis was infiltrating ductal carcinoma in all cases. None of the microme tastases cases showed any relationship with tumor grade, tumor size, expression of ER and PR, patient survival rate or recurrence rate. The most useful marker to detect micrometastases was pancytokeratin. CONCLUSION The results of this study indicate that micrometastasis of axillary lymph nodes does not carry any independent prognostic significance.
PURPOSE The purpose of this study was to develop and test an Information Needs Scale for Korean outpatients undergoing chemotherapy (INS-C). MATERIALS AND METHODS Thirty-three items of the INS-C had content validity based upon findings in the literature and the experiences of expert oncology physicians and nurses.
Each item consisted of a five-point Likert scale from 1 (don't want to know) to 5 (want to know very much). The items were administered to 175 Korean outpatients undergoing chemotherapy. The data obtained was analysed using a factor analysis for construct validity and Cronabch's alpha for internal consistent reliability. RESULTS From the factor analysis, six subscales were derived significantly. The six subscales explained 64.62% of the variance. The subscales were named Side-Effects/Investigative Tests (9 items), Spread of Disease (4 items), Financial Cost (2 items), Treatment (7 items), Activities/ Eating (6 items), and Interrelationships/Support (5 items). The Cronbach's alpha of the total INS-C was .95, and the alpha of the subscales ranged from .77 to .91. CONCLUSION The present study suggests that the INS-C is a reliable and valid instrument to measure the information needs of outpatients undergoing chemotherapy. Health professionals caring for patients with cancer should assess the informational needs of their patients using a reliable and valid instrument and be prepared to provide accurate information.
Citations
Citations to this article as recorded by
Psychometric Evaluation of a Need Scale for Cancer Patients Undergoing Follow-up Care Eun-Hyun Lee, Seongmi Moon, Soo-Yeon Cho, Young Taek Oh, Mison Chun, Sung Hwan Kim, Jae-Sung Kim, Hye Kyung Kim Journal of Korean Academy of Nursing.2010; 40(4): 551. CrossRef
PURPOSE Helicobacter pylori (H. pylori) is now generally accepted to be strongly associated with the development of gastric cancer, as well as intakes of some salted foods, charred foods, etc. To evaluate the association among dietary habits, H. pylori infection, and early gastric cancer in Koreans, a hospital based case-control study was conducted.
Material and Method: A total of 268 persons participated in this case-control study. Sixty nine patients were newly diagnosed as an early gastric cancer (EGC) at the Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, Seoul, Korea. One hundred ninety-nine subjects with no symptoms who visited the Health Promotion Center for their general checkups were selected as the controls. All subjects were examined for H. pylori infection, biochemical blood test the life style, and dietary habit were interviewed by a trained dietition with semi-quantitative food frequency question naire (FFQ) and adaptive salt concentration were taste evaluated. RESULTS H. pylori seropositivity was observed in 88.4% in cases, as compared with 74.9% in controls (OR=2.5, 95% CI: 1.1-5.7). The adaptive salt concentration was associated with early gastric cancer risk (chi-squir=50.8, p<0.001).
The analysis of food intake frequency demonstrated that early gastric cancer risk was reduced by the intake of clear soups, raw vegetables, fruits and juices, beef with vegetables and soybean curds. On the other hand, high intake of salt-fermented fish and kimchi elevated the risk of early gastric cancer. CONCLUSION These results suggest that some dietary factors and H. pylori infection have a significant association with the development of early gastric cancer.
Citations
Citations to this article as recorded by
Dietary intake and cancer incidence in Korean adults: a systematic review and meta-analysis of observational studies Ji Hyun Kim, Shinyoung Jun, Jeongseon Kim Epidemiology and Health.2023; 45: e2023102. CrossRef
Effect of dietary vitamin C on gastric cancer risk in the Korean population Bach Viet Hoang, Jeonghee Lee, Il Ju Choi, Young-Woo Kim, Keun Won Ryu, Jeongseon Kim World Journal of Gastroenterology.2016; 22(27): 6257. CrossRef
Epidemiology and screening of gastric cancer in Korea Minkyo Song, Hwi-Won Lee, Daehee Kang Journal of the Korean Medical Association.2015; 58(3): 183. CrossRef
Gastric Cancer Epidemiology in Korea Aesun Shin, Jeongseon Kim, Sohee Park Journal of Gastric Cancer.2011; 11(3): 135. CrossRef
Fresh and pickled vegetable consumption and gastric cancer in Japanese and Korean populations: A meta‐analysis of observational studies Hyun Ja Kim, Sun Young Lim, Jung‐Sug Lee, Sohee Park, Aesun Shin, Bo Youl Choi, Taichi Shimazu, Manami Inoue, Shoichiro Tsugane, Jeongseon Kim Cancer Science.2010; 101(2): 508. CrossRef
Identifying the Risk Factors Through the Development of a Predictive Model for Gastric Cancer in South Korea Dong-Suk Lee, Han-Kwang Yang, Jong-Won Kim, Jeong-Whan Yook, Seong-Hoon Jeon, Sung-Hak Kang, Young-Ju Kim Cancer Nursing.2009; 32(2): 135. CrossRef
So Young Yoon, Kyong Hwa Park, Sang Chul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Jae Seon Kim, Chang Duck Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim
Cancer Res Treat. 2002;34(2):111-116. Published online April 30, 2002
PURPOSE To evaluate the efficacy and toxicity of a Gemcitabine, UFT-E, Leucovorin combination chemotherapy in the treatment of advanced pancreatic adenocarcinoma.
PATIENTS AND METHODS: Patients <=70 years, with no prior chemotherapy and with bidimensionally measurable advanced pancreatic adenocarcinoma, ECOG performance status <=2, and adequate bone marrow, kidney, and liver function were eligible for this trial. Eligibility criteria for clinical benefit assessment were pain with at least a daily analgesic consumption of two nonsteroidal anti-inflammatory drugs or a Karnofsky performance status between 50 and 70. Treatment consisted of 1,000 mg/m2 of Gemcitabine on days 1, 8 and 15, repeated every 4 weeks, with UFT-E administered orally 500 mg-700 mg by body surface area (BSA). Leucovorin was administered 45 mg/day orally. Dosages of UFT-E and Leucovorin were divided and administered three times per day from day 1 to day 21. After 7 days of rest, UFT-E and Leucovorin were administered repeatedly. RESULTS Twenty-three patients were enrolled between April 1999 to April 2000. Eighty two cycles (median, four cycles) were delivered to all patients. The objective response rate was 15.8% in 19 assessable patients and 13.0% in the intent-to-treat population. Twelve patients (57.9%) displayed stable disease. Grade 3 or 4 neutropenia occurred in 30.4% of patients, nausea/vomiting in 8.3%, diarrhea in 4.3%, and mucositis in 4.3%. The median time to progression was 8 months. The median survival was 8 months in the assessable population and 6 months in the intent-to-treat population Clinical benefit was achieved in 11 (57.9%) of 19 assessable patients. CONCLUSION Gemcitabine, UFT-E, Leucovorin combination chemotherapy is a well-tolerated and safe regimen in cases of advanced pancreatic adenocarcinoma. Although the response rate is low, it shows a survival benefit and clinical benefit and deserves further evaluation in a phase III trial.
Citations
Citations to this article as recorded by
Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study Kyung Hee Lee, Min Kyoung Kim, Yeol Hong Kim, Baek Yeol Ryoo, Ho Yeong Lim, Hong Suk Song, Hoon Kyo Kim, Myung Ah Lee, Seock Ah Im, Heung Moon Chang, Jae Yong Cho, Dae Young Zang, Bong Seog Kim, Jun Suk Kim Cancer Chemotherapy and Pharmacology.2009; 64(2): 317. CrossRef
PURPOSE beta-catenin is an intracellular protein that is an integral component of the cadherin-mediated cell-cell interaction and a downstream transcriptional activator in the wnt signal transduction pathway. Inappropriate activation of beta-catenin has recently been implicated in the development of hepatocellular carcinoma and cholangiocarcinoma. Nuclear beta-catenin expression is strongly associated with gene mutation. This study was designed to evaluate the pattern of beta-catenin expression between hepatocellular carcinoma and cholangiocarcinoma. MATERIALS AND METHODS Immunohistochemical expression of beta-catenin was studied in 7 normal livers, 33 hepatocellular carcinomas and 20 cholangiocarcinomas, that were formalin fixed and paraffin embedded. RESULTS beta-catenin was expressed mainly in the cytoplasmic membrane of the normal hepatocytes and bile ducts. Nuclear expressions, not noted in the normal liver, were noted in 30% of the hepatocellular carcinomas and 10% of the cholangiocarcinomas. And, nuclear expression was more common in the high grade (50%) hepatocellular carcinomas than the low grade (18%) hepatocellular carcinomas (p<=0.05). CONCLUSION The above results indicate that nuclear expression of beta-catenin is observed in the carcinoma but not the normal liver, and is associated with high grade liver carcinoma.
Citations
Citations to this article as recorded by
Guanine nucleotide exchange factor T exerts the cancer-promoting function in cholangiocarcinoma by enhancing the Wnt-GSK-3β-β-catenin cascade via regulation of Rac1/Cdc42 Xifang Wang, Xiaomin Zhang, Jingying Sun, Yang Sun, Yuan Zhang, Li He, Ping Wang, Feng Li, Chao Sun Toxicology and Applied Pharmacology.2023; 467: 116492. CrossRef
Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity Elisa Lozano, Paula Sanchon-Sanchez, Ana Morente-Carrasco, Luis Miguel Chinchilla-Tábora, José L. Mauriz, Paula Fernández-Palanca, Jose J. G. Marin, Rocio I. R. Macias Cells.2023; 12(8): 1141. CrossRef
Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma Guo-Feng Zhang, Ling Qiu, Shu-Li Yang, Jia-Cheng Wu, Tong-Jun Liu Bioscience Reports.2020;[Epub] CrossRef
β-Catenin expression is associated with cell invasiveness in pancreatic cancer Jin Niang Nan, Ok Ran Kim, Myung Ah Lee The Korean Journal of Internal Medicine.2019; 34(3): 618. CrossRef
A Role for the WNT Co-Receptor LRP6 in Pathogenesis and Therapy of Epithelial Cancers Jennifer Raisch, Anthony Côté-Biron, Nathalie Rivard Cancers.2019; 11(8): 1162. CrossRef
Beta-Catenin Downregulation Contributes to Epidermal Growth Factor-induced Migration and Invasion of MDAMB231 Cells Arang Kwon, Hyun-Jung Park, Jeong-Hwa Baek International Journal of Oral Biology.2018; 43(3): 161. CrossRef
Genetic alterations of Wnt signaling pathway–associated genes in hepatocellular carcinoma Young‐Dae Kim, Chang‐Hwan Park, Hyun‐Soo Kim, Sung‐Kyu Choi, Jong‐Sun Rew, Dong‐Yi Kim, Yang‐Suk Koh, Kyung‐Woon Jeung, Kyung‐Hwa Lee, Ji‐Shin Lee, Sang‐Woo Juhng, Jae‐Hyuk Lee Journal of Gastroenterology and Hepatology.2008; 23(1): 110. CrossRef
PURPOSE Insulin-like growth factor-I (IGF-I) is an important mitogen in many types of malignancies. The purpose of this study was to evaluate the role of the IGF system on cell proliferation and cell death in mouse lung cancer cell lines (3LL). MATERIALS AND METHODS Northern analysis was performed in 3LL cells. We evaluated the phosphorylation of IGF-I receptor (IGF-IR) with IGF-I stimulation. MTT assay was performed after treating 3LL cells with IGF-I and the treatment effect on cell death in the presence of anticancer drug was investigated. RESULTS Northern analysis revealed the presence of IGF-I and IGF-IR mRNA expression in 3LL cells. IGF-I increased cellular proliferation in serum free media. IGF-I also stimulated the tyrosine phosphorylation of two proteins: one, with a molecular mass of 95 kDa, was the beta-subunit of IGF-IR; the other, with an approximate molecular mass of 185 kDa, was originally identified as the insulin receptor substrate-I (IRS-I). IGF-I at a low concentration inhibited the cell death induced by adriamycin. CONCLUSION IGF-I, a mitogen through the phosphorylation of the IGF-IR beta-subunit, acts as a survival factor to inhibit cell death. Therefore, these findings suggest that IGF-I and IGF-IR are involved in both the cell proliferation and cell death associated with cancer cell growth.
PURPOSE In order to investigate the role of Fas on the chemosensitivity of cancer cells in regards to chemotherapeutic agents, the Fas/FasL signaling pathway of apoptosis was explored in human hepatoma cells. MATERIALS AND METHODS Fas expression of hepatoma cells including Chang, Huh7, HepG2, and Hep3B cells, was determined by RT-PCR and flow cytometry analysis. Cell viability was measured by MTT assay and apoptosis was assessed by DNA fragmentation assay. The catalytic activity of the caspase-family proteases including caspase-3, 6, 8, and 9 proteases, was tested using fluorogenic biosubstrates.
The expression of apoptotic mediators including cytochrome c, PARP, and Bcl2 family proteins were measured from cytosolic and mitochondrial compartments. Mitochondrial membrane potential was measured by fluorescence staining with JC-1, rhodamine 123. RESULTS Fas mRNA was constitutively expressed in Chang and HepG2 as defined as Fas (+) cells, but not in Huh7 and Hep3B cells, defined as Fas (-) cells. Fas (+) cells were markedly sensitive to 5-FU whereas Fas (-) cells were resistant and able to survive. 5-FU increased Fas expression of Fas (+) HepG2 cells and simultaneously resulted in apoptotic death, characterized by the ladder-pattern fragmentation of genomic DNA. Moreover, it increased the catalytic activity of caspase-8 protease, which eventually cleaved the Bid into truncated Bid which translocated into mitochondria only in Fas (+) cells. It also increased the caspase-9 protease activity with Bax expression, cytosolic release of cytochrome c, and mytochondrial dysfunction only in Fas (+) HepG2 cells. Furthermore, 5-FU increased the enzymatic activity of caspase-3 protease with PARP digestion in HepG2 cells. CONCLUSION 5-FU exerted cytotoxicity against hepatoma cells via activation of Fas-mediated apoptotic signaling including caspase cascades and mytochondrial dysfunction.
Our data suggests that Fas may be an important modulator of the chemosensitivity of cancer cells vis- -vis anticancer chemotherapeutic agents.
Citations
Citations to this article as recorded by
Sex-dependent liver cancer xenograft models for predicting clinical data in the evaluation of anticancer drugs Sungryong Oh, Joohee Jung Laboratory Animal Research.2021;[Epub] CrossRef
Lead bioactive compounds of Aloe vera as potential anticancer agent Ranabir Majumder, Chandan Kanta Das, Mahitosh Mandal Pharmacological Research.2019; 148: 104416. CrossRef
Extract from Artemisia annua Linn? Induces Apoptosis through the Mitochondrial Signaling Pathway in HepG2 Cells Bo Min Kim, Guen Tae Kim, Eun Ji Kim, Eun Gyeong Lim, Sang-Yong Kim, Young Min Kim Journal of the Korean Society of Food Science and Nutrition.2016; 45(12): 1708. CrossRef
Dexamethasone Inhibits TRAIL- and Anti-cancer Drugs-induced Cell Death in A549 Cells through Inducing NF-κB-independent cIAP2 Expression Youn Seup Kim, Jae Seuk Park, Young Koo Jee, Kye Young Lee Cancer Research and Treatment.2004; 36(5): 330. CrossRef
PURPOSE We evaluated the survival rate, prognostic factors and patterns of failure in malignant and atypical meningiomas, and investigated the role of radiation therapy in the treatment of these tumors. MATERIALS AND METHODS We retrospectively reviewed nineteen patients treated at Asan Medical Center between Mar. 1994 and Jun. 2000 with histologically confirmed malignant or atypical meningiomas. The median patient age was 52 years.
The extent of surgery prior to radiation was gross total resection in 13 and subtotal resection in 6. Eleven patients were referred for radiation immediately after diagnosis and the remainder after at least one recurrence. All patients received megavoltage radiation to a median dose of 55.8 Gy.
The median follow-up period was 41 months. RESULTS Eleven patients (57.9%) showed no evidence of disease, five patients died of meningioma and three were alive with disease. The 5-year overall and relapse-free survivals were 75.9 and 50.6%, respectively. There were no statistically significant prognostic factors found to be associated with relapse-free survival by univariate or multivariate analysis. During the follow-up period, no significant treatment-related complications were detected. CONCLUSION The major patterns of failure were in-field recurrence. In order to reduce local failure, a higher radiation dose may be needed and a high precision therapy should be considered.
Citations
Citations to this article as recorded by
Revisiting Adjuvant Radiotherapy After Gross Total Resection of World Health Organization Grade II Meningioma Christopher S. Graffeo, Heather E. Leeper, Avital Perry, Joon H. Uhm, Daniel J. Lachance, Paul D. Brown, Daniel J. Ma, Jamie J. Van Gompel, Caterina Giannini, Derek R. Johnson, Aditya Raghunathan World Neurosurgery.2017; 103: 655. CrossRef
PURPOSE The prognosis of non-Hodgkin's lymphoma (NHL) is disappointing for patients who experience primary treatment failure or relapse after an initial response. Patients in relapse may respond again to chemotherapy, however the time to disease progression becomes shorter and eventually the disease becomes resistant. The aim of this study was to evaluate the efficacy and safety of the MINE regimen in the treatment of patients with relapsed or refractory NHL.
Material and Methods: Forty-three pretreated patients with a median age of 56 years were enrolled into the study between October 1995 and June 2000. Most patients (60.5%) had a performance status of 0 to 1, and a diffuse large cell subtype (55.8%). Seventy-four percent of patients had stage III or IV disease at the start of MINE treatment. Eighteen (41.9%) patients had complete response, 5 (11.6%) had partial response, and 20 (46.5%) had failed to respond to prior therapy. Ifosfamide 4 g/m2 was divided over 3 days and administered IV over a 1 hour period. Mitoxantrone 8 mg/m2 was administered as a short IV infusion on day 1. Etoposide (65 mg/m2/day) was infused over 1 hour on days 1 to 3. A total of 144 cycles was administered, with a mean of 3.34 cycles per patient (range, 1-8). The mean relative dose intensity was 87.4%. RESULTS 1) Nine patients achieved a complete response and nine patients achieved a partial response, resulting in an overall response rate of 43.8% of the 41 assessable patients. 2) The median survival time was 6 months (95% CI, 4 to 8 months), and the median time to failure was 5 months (95% CI, 3 to 7 months). 3) A statistically significant association with complete response rates was found for complete response to prior therapy (p=0.049). The significant factors for overall survival were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.012, respectively). The significant factors for time to treatment failure were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.044, respectively). 4) The main result of toxicity of MINE was bone marrow suppression. CONCLUSION The response to MINE chemotherapy and serum 2-microglobulin were both independent prognostic factors for overall survival and time to treatment failure. As the median time to treatment failure for complete responses was 14 months, the best use of this regimen could be in a strategy that includes prompt consolidation of a complete response with intense chemotherapy, with or without hematopoietic stem cell rescue.
Citations
Citations to this article as recorded by
Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy–intolerant lymphoma patients Akihiro Ohmoto, Shigeo Fuji Expert Review of Anticancer Therapy.2021; 21(7): 715. CrossRef
Reported cases of gastrosplenic fistulas are extremely rare in the literature. Malignancy is the primary cause in 50% of patients, followed by perforated peptic ulcer (40%).
Fistulas can cause spleen rupture and potential bleeding that threaten the life of the patient. Lymphoma is the most common cause of malignancy complicated with gastrosplenic fistula. Most gastrosplenic fistulae caused by lymphoma eventually close following chemotherapy, although splenectomy should be performed to avoid further complications. We experienced a case of non-Hodgkin's lymphoma complicated with gastrosplenic fistula in a 21 year-old man. He was admitted to our hospital because of LUQ mass. On the abdominal CT, a splenic mass with central necrosis and gas was discovered. The biopsy specimen of the stomach and spleen displayed diffuse, large B cell type non-Hodgkin's lymphoma. After one cycle of CHOP chemotherapy, the LUQ mass was markedly regressed although the gastrosplenic fistula was still present on the follow-up CT. The fistula was treated by splenectomy and a partial resection of gastric fundus. Follow-up chemotherapy was continued after surgery.
Citations
Citations to this article as recorded by
SPONTANEOUS GASTROSPLENIC FISTULA: AN UNUSUAL PRESENTATION OF DIFFUSE LARGE B CELL LYMPHOMA Hale Bülbül, Kader Irak, Selin Berk, Yusuf Ulusoy, Mesut Ayer Gastroenterology Nursing.2022; 45(1): 63. CrossRef
Gastro-Splenic Fistula Related to Large B Cell Lymphoma Diana Triantafyllopoulou, Ioannis Gkikas, Jagdish Adiyodi, Iain Crossingham, Shofiq Al-Islam, Muhammad Shahbaz Alam, Neil Sahasrabudhe, Ambareen Kausar, Ali Bin Ayub, Hazel Cowburn, Lisa Fox, Maqsood Punekar, Marian Macheta, Reuben Tooze Reports.2020; 3(2): 17. CrossRef
Hand-assisted laparoscopic approach for the treatment of gastrosplenic fistula: A case report and review of the literature Virginia Gallo, Luigi Pugliese, Francesco S. Latteri, Andrea Peri Laparoscopic, Endoscopic and Robotic Surgery.2020; 3(4): 120. CrossRef
Successful Treatment of Gastrosplenic Fistula Arising from Diffuse Large B-Cell Lymphoma with Chemotherapy: Two Case Reports Makoto Saito, Kencho Miyashita, Yosuke Miura, Shinpei Harada, Reiki Ogasawara, Koh Izumiyama, Akio Mori, Masanori Tanaka, Masanobu Morioka, Takeshi Kondo Case Reports in Oncology.2019; 12(2): 376. CrossRef
Gastrosplenic fistula occurring in lymphoma patients: Systematic review with a new case of extranodal NK/T-cell lymphoma Dong Hyeok Kang, Jimi Huh, Jong Hwa Lee, Yoong Ki Jeong, Hee Jeong Cha World Journal of Gastroenterology.2017; 23(35): 6491. CrossRef
Lymphoma Causing Gastrosplenic Fistula Revealed by FDG PET/CT Trent P. Wang, Mohan Doss, Jeffrey L. Tokar, Sanjay Reddy, Stefan K. Barta, Jian Q. Yu Clinical Nuclear Medicine.2017; 42(11): 890. CrossRef
Gastrosplenic Fistula From Hodgkin's Lymphoma Carolyn D. Seib, Flavio G. Rocha, Dick G. Hwang, Brent T. Shoji Journal of Clinical Oncology.2009; 27(20): e15. CrossRef